Viatris buyout at $36.50 cash drives Pacira; EU deal adds growth
Viatris to acquire Pacira for $36.50/share in cash Viatris agreed to buy Pacira for $36.50 per share in cash, a 45% premium, sending the stock up 44% intraday. The deal is expected to close by end-2026, after which Pacira will be a wholly owned subsidiary and delisted. This sets a firm cash floor and is the dominant driver.
The buyout is the single biggest force moving PCRX, capping its price near the offer and driving the period's huge gain.
EU/UK EXPAREL licensing deal with Molteni Pacira signed an exclusive deal with Molteni to commercialize EXPAREL in the EU and UK, receiving an upfront payment, supply price, and royalties. First sales are expected in 2027. This expands long-term revenue potential, though it is now secondary to the buyout.
It shows a new growth avenue for Pacira's main product, supporting the value of the business being acquired.
Q2 profit swing and guidance cut after Iovera sale Pacira swung to a $4.65M profit and beat estimates, but cut full-year 2026 revenue guidance to $735–760M after selling its Iovera business to Zimmer Biomet. The guidance cut reflects lost revenue, while the profit and reimbursement wins for EXPAREL and ZILRETTA are positives.
It explains the underlying business performance and the reason for lower guidance, a key counterweight to the buyout news.